132 related articles for article (PubMed ID: 37966980)
1. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
El-Ashwah S; Salmanton-García J; Bilgin YM; Itri F; Žák P; Weinbergerová B; Verga L; Omrani AS; Silva MGD; Szotkowski T; Marchetti M; Buquicchio C; Nucci M; Schönlein M; Farina F; Besson C; Prezioso L; Nizamuddin S; Dávila-Valls J; Martín-Pérez S; Bonuomo V; Van Doesum J; Tisi MC; Passamonti F; Méndez GA; Meers S; Maertens J; López-García A; Glenthøj A; Bonnani M; Rinaldi I; Ormazabal-Vélez I; Labrador J; Kulasekararaj A; Espigado I; Demirkan F; De Jonge N; Collins GP; Calbacho M; Blennow O; Al-Khabori M; Adžić-Vukičević T; Arellano E; Mišković B; Mladenović M; Nordlander A; Ráčil Z; Ammatuna E; Cordoba R; Hersby DS; Gräfe S; Emarah Z; Hanakova M; Sacchi MV; Ijaz M; Rahimli L; Nunes Rodrigues R; Zambrotta GPM; Marchesi F; Cornely OA; Pagano L
Leuk Lymphoma; 2024 Feb; 65(2):199-208. PubMed ID: 37966980
[TBL] [Abstract][Full Text] [Related]
2. Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization.
Civettini I; Antolini L; Brioschi F; Zambrotta GPM; Guglielmana V; Gambacorti-Passerini C
Cancer Med; 2023 Apr; 12(8):9662-9667. PubMed ID: 37039261
[TBL] [Abstract][Full Text] [Related]
3. What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
Delgado N; Torres A
Curr Oncol Rep; 2022 May; 24(5):645-650. PubMed ID: 35218499
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Breccia M; Abruzzese E; Accurso V; Attolico I; Barulli S; Bergamaschi M; Binotto G; Bocchia M; Bonifacio M; Caocci G; Capodanno I; Castagnetti F; Cavazzini F; Crisà E; Crugnola M; Stella De Candia M; Elena C; Fava C; Galimberti S; Gozzini A; Gugliotta G; Intermesoli T; Iurlo A; La Barba G; Latagliata R; Leonetti Crescenzi S; Levato L; Loglisci G; Lucchesi A; Luciano L; Lunghi F; Luzi D; Malato A; Cristina Miggiano M; Pizzuti M; Pregno P; Rapezzi D; Rege-Cambrin G; Rosti G; Russo S; Sancetta R; Rita Scortechini A; Sorà F; Sportoletti P; Stagno F; Tafuri A; Tiribelli M; Foà R; Saglio G
Br J Haematol; 2022 Feb; 196(3):559-565. PubMed ID: 34636033
[TBL] [Abstract][Full Text] [Related]
5. Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population.
Graf I; Herndlhofer S; Kundi M; Greiner G; Sperr M; Hadzijusufovic E; Valent P; Sperr WR
Eur J Haematol; 2023 Jan; 110(1):67-76. PubMed ID: 36193973
[TBL] [Abstract][Full Text] [Related]
6. Is COVID-19 less severe in CML patients than in those with other haematological cancers?
Claudiani S
Br J Haematol; 2022 Feb; 196(3):471-472. PubMed ID: 34708401
[No Abstract] [Full Text] [Related]
7. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
Bonifacio M; Tiribelli M; Miggiano MC; Abruzzese E; Binotto G; Scaffidi L; Cordioli M; Damiani D; Di Bona E; Trawinska MM; Tanasi I; Dubbini MV; Velotta V; Ceccarelli G; Pierdomenico E; Lo Schirico M; Semenzato G; Ruggeri M; Fanin R; Tacconelli E; Pizzolo G; Krampera M
Cancer Med; 2021 Sep; 10(18):6310-6316. PubMed ID: 34464516
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
Pagano L; Salmanton-García J; Marchesi F; Busca A; Corradini P; Hoenigl M; Klimko N; Koehler P; Pagliuca A; Passamonti F; Verga L; Víšek B; Ilhan O; Nadali G; Weinbergerová B; Córdoba-Mascuñano R; Marchetti M; Collins GP; Farina F; Cattaneo C; Cabirta A; Gomes-Silva M; Itri F; van Doesum J; Ledoux MP; Čerňan M; Jakšić O; Duarte RF; Magliano G; Omrani AS; Fracchiolla NS; Kulasekararaj A; Valković T; Poulsen CB; Machado M; Glenthøj A; Stoma I; Ráčil Z; Piukovics K; Navrátil M; Emarah Z; Sili U; Maertens J; Blennow O; Bergantim R; García-Vidal C; Prezioso L; Guidetti A; Del Principe MI; Popova M; de Jonge N; Ormazabal-Vélez I; Fernández N; Falces-Romero I; Cuccaro A; Meers S; Buquicchio C; Antić D; Al-Khabori M; García-Sanz R; Biernat MM; Tisi MC; Sal E; Rahimli L; Čolović N; Schönlein M; Calbacho M; Tascini C; Miranda-Castillo C; Khanna N; Méndez GA; Petzer V; Novák J; Besson C; Duléry R; Lamure S; Nucci M; Zambrotta G; Žák P; Seval GC; Bonuomo V; Mayer J; López-García A; Sacchi MV; Booth S; Ciceri F; Oberti M; Salvini M; Izuzquiza M; Nunes-Rodrigues R; Ammatuna E; Obr A; Herbrecht R; Núñez-Martín-Buitrago L; Mancini V; Shwaylia H; Sciumè M; Essame J; Nygaard M; Batinić J; Gonzaga Y; Regalado-Artamendi I; Karlsson LK; Shapetska M; Hanakova M; El-Ashwah S; Borbényi Z; Çolak GM; Nordlander A; Dragonetti G; Maraglino AME; Rinaldi A; De Ramón-Sánchez C; Cornely OA;
J Hematol Oncol; 2021 Oct; 14(1):168. PubMed ID: 34649563
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in persons with chronic myeloid leukaemia.
Li W; Wang D; Guo J; Yuan G; Yang Z; Gale RP; You Y; Chen Z; Chen S; Wan C; Zhu X; Chang W; Sheng L; Cheng H; Zhang Y; Li Q; Qin J; ; Meng L; Jiang Q
Leukemia; 2020 Jul; 34(7):1799-1804. PubMed ID: 32424293
[TBL] [Abstract][Full Text] [Related]
10. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.
Elsir Khair H; Ahmed Mohamed B; Yousef Nour B; Ali Waggiallah H
Pak J Biol Sci; 2022 Jan; 25(2):175-181. PubMed ID: 35234007
[TBL] [Abstract][Full Text] [Related]
12. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia in 2007.
Sessions J
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S4-9. PubMed ID: 18056931
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study.
Ector GICG; Huijskens EGW; Blijlevens NMA; Westerweel PE
Leukemia; 2020 Sep; 34(9):2533-2535. PubMed ID: 32641732
[No Abstract] [Full Text] [Related]
17. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
18. Non-treatment-related chronic myeloid leukemia as a second malignancy.
Specchia G; Buquicchio C; Albano F; Liso A; Pannunzio A; Mestice A; Rizzi R; Pastore D; Liso V
Leuk Res; 2004 Feb; 28(2):115-9. PubMed ID: 14654074
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.
Breccia M; Abruzzese E; Bocchia M; Bonifacio M; Castagnetti F; Fava C; Galimberti S; Gozzini A; Gugliotta G; Iurlo A; Latagliata R; Luciano L; Pregno P; Rege-Cambrin G; Rosti G; Stagno F; Tiribelli M; Foà R; Saglio G;
Leukemia; 2020 Aug; 34(8):2260-2261. PubMed ID: 32555369
[No Abstract] [Full Text] [Related]
20. BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
Paramita DK; Hutajulu SH; Syifarahmah A; Sholika TA; Fatmawati S; Aning S; Sulistyawati D; Wahyuni S; Taroeno-Hariadi KW; Kurnianda J
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1545-1550. PubMed ID: 32592347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
